contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


genovis-ab-genovis-launches-fabricatorr-xtra-next-generation-enzyme-for-future-antibody-therapeutics

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund. 

Genovis

Genovis AB, a leading provider of innovative enzyme technologies, announce the launch of FabRICATOR® Xtra, the second generation of its widely used FabRICATOR (IdeS) enzyme. This newly developed...

<div class="abstract">Genovis AB, a leading provider of innovative enzyme technologies, announce the launch of FabRICATOR® Xtra, the second generation of its widely used FabRICATOR (IdeS) enzyme. This newly developed enzyme is specifically designed to address the evolving needs of biopharmaceutical development by efficiently digesting next-generation antibody-based therapeutics with mutations designed to enhance their therapeutic properties.</div>New generations of antibody-based therapeutics, designed with structural mutations, have posed a challenge to traditional enzyme technologies. These therapeutic antibodies, while offering enhanced efficacy and stability, could not be digested with legacy FabRICATOR® (IdeS), preventing researchers from utilizing the efficient middle-level workflows previously enabled by the enzyme.FabRICATOR® Xtra is an innovative solution to this challenge. With its ability to precisely and efficiently digest novel engineered antibody formats, Genovis is once again advancing analytical workflows for developers of future therapeutics antibodies. The new enzyme offers the same high level of accuracy and speed that users have come to expect from FabRICATOR®, ensuring that it can seamlessly integrate into existing workflows while supporting the development of future antibody-based therapies."With FabRICATOR® Xtra, we're excited to offer a solution to our customers working at the forefront of antibody-based therapeutic innovation. Our next-generation enzyme supports more complex and mutated antibody formats, giving researchers the tools they need to continue developing the therapies of tomorrow", said Fredrik Olsson, CEO at Genovis.FabRICATOR® Xtra builds upon the success of its predecessor by maintaining the same precision, accuracy, and efficiency, while extending its utility to novel formats. Genovis remains committed to supporting the biopharmaceutical industry with innovative, high-performance tools that address the demands of modern therapeutic development.For more information on FabRICATOR® Xtra please visit:&nbsp;<a href="https://www.genovis.com/smartenzymes/antibody-digestion/fabricator-xtra/">https://www.genovis.com/smartenzymes/antibody-digestion/fabricator-xtra/</a>

Genovis AB: Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Helsinki Stock Exchange is cheap

Drug development investment: Value creation through M&As and licensing agreements

Valuation methods: Valuation multiples

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!